Please log in
You must be logged in to send the contact request.
Manage stand orders
Select Option
SYnAbs S.A.
48 rue Auguste Piccard,
6041
Gosselies
Belgium
Belgium
Submit your contact details
Provide your contact details to the exhibitor. Optionally, you may also add a personal message.
Your name, phone number, and e-mail address are subject to the submission of personal data. Messe Düsseldorf GmbH expressly points out that for a data transmission into third countries, for which no adequacy decision of the EU-commission is on hand certifying an adequate level of protection of personal data, it is not ensured that there are appropriate safeguards for the protection of personal data on hand.
An error has occurred
Please check your internet connection or try again later.
Message has been sent
Your message to the exhibitor was sent successfully.
This company is co-exhibitor of
Wallonia Export & Investment (AWEX)
Contact
Please log in
You must be logged in to use matchmaking
Please log in for matchmaking
Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.
Let's get started!
Welcome to Matchmaking. Would you like to get in touch with ?
Visit us
16 Nov 2020
Topic
all-day
Custom monoclonals generation against haptens and difficult antigens
- Antigen design and production: carbohydrates, lipids, neoepitopes, transmembrane proteins, toxins, epigenetic modifications
- Mouse, Rats & Guinea pigs immunization schedules (DNA immunization, footpad...)
- Fusion with proprietary myeloma cell lines
- Screening against target antigen and cloning
- Antibodies animal-free manufacturing and purification
- Serum-free adaptation,
- Up-stream & Down-Stream Processing development, scale-up and manufacturing up to several grams,
- Development of custom immunoassays
- Antibody engineering (ScFv, bispecific,...) & Humanization for therapeutic purposes
17 Nov 2020
Topic
08:00
Off-the-shelf unique primary monoclonal antibodies against complex antigens
- Anti-DHT
- Anti-aflatoxin
- Anti-KIAA1199
- Anti-SERPin
18 Nov 2020
Topic
all-day
Off-the-shelf unique secondary monoclonal antibodies
- Anti-human (anti IgG4, anti-IgG, anti-IgM, anti-IgA, anti-IgE...)
- Anti-camel (anti-VHH)
- Anti-rat
- Anti-mouse
- Anti-horse
- Anti-chicken
Our range of products
Product categories
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.01 Immuno assay testing
Immuno assay testing
- Rat monoclonal antibodies against human repertoire
- Mouse monoclonal antibodies against rat isotypes
- Irrelevant and isotype control antibodies
- Guinea pig monoclonal antibodies against hormone steroid
- Monoclonal antibodies against mycotoxins
- Rat monoclonal antibodies against camel repertoire
- Custom mAb generation against difficult antigen and haptens
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.02 Diagnostic rapid tests
Diagnostic rapid tests
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.03 Diagnostic tests for cancer
Diagnostic tests for cancer
- 03 Diagnostic tests
- 03.04 Microbiology testing
- 03.04.03 Rapid tests in microbiology
Rapid tests in microbiology
Our products
Product category: Immuno assay testing
Rat monoclonal antibodies against human repertoire
- LO-hK-3 Rat anti-Human kappa light chain
- LO-hL-2 Rat anti-Human lambda light chain
- LO-hM-7 Rat anti-Human IgM heavy chain
- LO-hD-11 Rat anti-Human IgD heavy chain
- LO-hE-10 Rat anti-Human IgE heavy chain
- LO-hA-8 Rat anti-Human IgA1 heavy chain
- LO-hG-20 Rat anti-Human IgG heavy chain
- LO-hIL2-1 Rat anti-Human IL2
- LO-hIL2-2 Rat anti-Recombinant Human IL2
- LO-hIL6-1 Rat anti-Human IL6
- LO-CD1-a Rat Human Human CD1
- LO-CD5-a Rat Human Human CD5
- LO-CD6-a Rat Human Human CD6
- LO-CD9 Rat Human Human CD9
- LO-CDw41 Rat anti-Human Platelets glycoprotein complex IIb-IIIa
- LO-MO1 Rat anti-Human CD14
- LO-PanB-a Rat anti- Human CDW78
- LO-Tact-1 Rat anti-Human IL2 receptor
- LO-HIV1-1 Rat anti-Human p24 HIV-1
- LO-hG4-1 Rat Human Human IgG4
Product category: Immuno assay testing
Mouse monoclonal antibodies against rat isotypes
- MARK-1 Mouse anti-Rat Kappa light chain
- MARK-3 Mouse anti-Rat Kappa light chain
- MARL-15 Mouse anti-Rat Rat Lambda light chain
- MAR(K+L) Mouse anti-Rat kappa + lambda light chain
- MARM-4 Mouse anti-Rat IgM heavy chain
- MARM-7 Mouse anti-Rat IgM heavy chain
- MARD-3 Mouse anti-Rat IgD heavy chain
- MARA-1 Mouse anti-Rat IgA heavy chain
- MARE-1 Mouse anti-Rat IgE heavy chain
- MARG1-1 Mouse anti-Rat IgG1 heavy chain
- MARG2a-1 Mouse anti-Rat IgG2a heavy chain
- MARG2b-8 Mouse anti-Rat IgG2b heavy chain
- MARG2c-3 Mouse anti-Rat IgG2c heavy chain
- MARG-COC-1 Mouse anti-Rat IgG1,IgG2a,IgG2b, IgG2c heavy chain
Product category: Immuno assay testing
Irrelevant and isotype control antibodies
- LO-DNP: rat anti-DiNitroPhenol
- MA-DNP: mouse anti-DiNitroPhenol
- IR202 : Rat IgM kappa
- IR22: Rat IgA kappa
- IR2: Rat IgE kappa
- IR595: Rat IgG1 kappa
- IR31: Rat IgG1 lambda
- IR418: Rat IgG2a kappa
- IR863 Rat / IgG2b kappa
- IR304 Rat / IgG2c kappa
Product category: Immuno assay testing
Custom mAb generation against difficult antigen and haptens
- Antigen design and production: carbohydrates, lipids, neoepitopes, transmembrane proteins, toxins, epigenetic modifications
- Mouse, Rats & Guinea pigs immunization schedules (DNA immunization, footpad...)
- Fusion with proprietary myeloma cell lines
- Screening against target antigen and cloning
- Antibodies animal-free manufacturing and purification
- Serum-free adaptation,
- Up-stream & Down-Stream Processing development, scale-up and manufacturing up to several grams,
- Development of custom immunoassays
- Antibody engineering (ScFv, bispecific,...) & Humanization for therapeutic purposes
Product category: Diagnostic rapid tests
Rat monoclonal antibodies against human repertoire
Anti-IgG, anti-IgM, and anti-IgA for the monitoring of immune response.
Already included in COVID-19 test rapid diagnostic tests!
Unlike the products marketed to date, the test developed by SYnabs, Coris BioConcept, Unisensor, and Bio- X Diagnostics, is the only rapid solution (developed in different formats) that can detect an immune response against two specific Coronavirus / Covid-19 "markers". This 100% Walloon innovation makes it possible to detect not only a greater number of people who have been contaminated but also to identify those who have developed a neutralizing, potentially protective immune response.
Already included in COVID-19 test rapid diagnostic tests!
Unlike the products marketed to date, the test developed by SYnabs, Coris BioConcept, Unisensor, and Bio- X Diagnostics, is the only rapid solution (developed in different formats) that can detect an immune response against two specific Coronavirus / Covid-19 "markers". This 100% Walloon innovation makes it possible to detect not only a greater number of people who have been contaminated but also to identify those who have developed a neutralizing, potentially protective immune response.
Product category: Rapid tests in microbiology
Antibiotic resistance identification
The objective of the RADAR project is to develop new tests for the identification of antibiotic resistance.
This project, carried out in partnership by the companies Coris BioConcept and Synabs, involves the creation of reagents necessary for the development of new tests as well as the improvement of existing tests in order to extend their field of use and enable Coris BioConcept to extend the R.E.S.I.S.T. range dedicated to these identifications.
This project, carried out in partnership by the companies Coris BioConcept and Synabs, involves the creation of reagents necessary for the development of new tests as well as the improvement of existing tests in order to extend their field of use and enable Coris BioConcept to extend the R.E.S.I.S.T. range dedicated to these identifications.
Product category: Diagnostic tests for cancer
Epigenetic modifications identification
The MENAC project aims to develop new tests for the identification of epigenetic changes in histones such as acetylations, methylations, phosphorylation, and mutations.
This project, carried out in partnership by Volition and Synabs, involves the creation of monoclonal antibodies necessary for the development of new tests for the early diagnosis of cancer in humans and animals.
This project, carried out in partnership by Volition and Synabs, involves the creation of monoclonal antibodies necessary for the development of new tests for the early diagnosis of cancer in humans and animals.
Company news
Date
Topic
08 Oct 2020
SYnabs, Unisensor, Coris BioConcept and Bio-X Diagnostics, have together developed a COVID individual rapid test that is a world premiere
Unlike the products marketed to date, the test developed by SYnabs, Coris BioConcept, Unisensor, and Bio- X Diagnostics, is the only rapid solution (developed in different formats) that can detect an immune response against two specific Coronavirus / Covid-19 "markers". This 100% Walloon innovation makes it possible to detect not only a greater number of people who have been contaminated but also to identify those who have developed a neutralizing, potentially protective immune response.
08 Oct 2020
SYnabs & Biokit announce strategic collaboration on valproic acid antigen
SYnAbs & Biokit, A Werfen Company are proud to announce their success in the development of the best anti-valproic acid monoclonal antibody of the market! This case study is a new proof of the high efficiency of SYnAbs technologies for the generation of antibodies against haptens.
24 Sep 2020
SYnAbs and Volition ink strategic deal on epigenetic modifications targeting
SYnabs will develop monoclonal antibodies of mice, rats, and guinea pigs against 16 different post-translational modifications on histones including methylation, acetylation, phosphorylation, and mutations.
About us
Company portrait
SYnAbs' mission is to generate innovative antibodies against poor immunogenic compounds and complex antigens. Either as a custom service, or as a catalog product, you can benefit from SYnAbs technologies to get access to singular monoclonal antibodies.
The benefits of SYnAbs unique technologies?
The benefits of SYnAbs unique technologies?
- Extreme specificity monoclonal antibodies
- Higher affinity binder monoclonal antibodies
- >90% success rate for small, difficult and poor immunogenic antigens
- Additional epitope recognition
- High and stable producer clones
- Access to multiple immune repertoires
- Raising antibodies against difficult to express antigens
- Generating antibodies against conformation sensitive targets thanks to DNA immunization
Company data
Sales volume
< 1 Mio US $
Export content
max. 75%
Number of employees
1-19
Foundation
2015
Area of business
Diagnostics